Back to search
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Neoplasms
Clinicaltrials.gov:
EU CTIS:
#2025-520927-26-00
Other:
#78278343PCR3001
Trials at a glance
Status
Enrolling
Condition
Metastatic Castration-resistant Prostate Neoplasms
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Best Supportive Care (BSC)
Pasritamig
Placebo
Age
18+ years old
Biological sex
Male
Placebo?
Yes
Trial start date
September 2, 2025
Trial end date
May 30, 2028
CT.gov ID
#NCT07164443
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Australia,
- Canada,
- Japan,
- Puerto Rico,
- Taiwan,
- United Kingdom,
- United States
Loading...
Enrolling
Bay Pines, Florida, United States, 33744
Enrolling
Québec, Quebec, Canada, G1J 1Z4
Enrolling
Myrtle Beach, South Carolina, United States, 29572
Enrolling
Lakewood, Colorado, United States, 80228
Enrolling
Portland, Oregon, United States, 97227
Enrolling
Boston, Massachusetts, United States, 02215
Enrolling
Metairie, Louisiana, United States, 70006
Enrolling
Murdoch, Australia, 6150
Enrolling
Spartanburg, South Carolina, United States, 29303
Enrolling
Kurralta Park, Australia, 5037
Enrolling
Kanazawa, Japan, 920 8641
Enrolling
Lancaster, Pennsylvania, United States, 17601
Enrolling
Fukuoka, Japan, 812 8582
Enrolling
Houston, Texas, United States, 77030
Enrolling
Bala-Cynwyd, Pennsylvania, United States, 19004
Enrolling
Taipei, Taiwan, 100
Enrolling
Springfield, Oregon, United States, 97477
Enrolling
Rio Piedras, Puerto Rico, 00935
Enrolling
Melbourne, Australia, 3000
Enrolling
Woolloongabba, Australia, 4102
Enrolling
Hato Rey, Puerto Rico, 00970
Enrolling
Aurora, Colorado, United States, 80012
Enrolling
Sutton, United Kingdom, SM2 5PT
Enrolling
Taipei, Taiwan, 112
Enrolling
Chattanooga, Tennessee, United States, 37404
Enrolling
Nashville, Tennessee, United States, 37203
Enrolling
Wichita Falls, Texas, United States, 76310
Enrolling
Manchester, United Kingdom, M20 4BX
Enrolling
Sakura, Japan, 285-8741
Enrolling
London, United Kingdom, WC1E 6BT
Enrolling
Cincinnati, Ohio, United States, 45219
Enrolling
Heidelberg, Australia, 3084
Enrolling
Omaha, Nebraska, United States, 68130
Enrolling
Yokohama, Japan, 236 0004
Enrolling
Yokosuka, Japan, 238 8558
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2025
